ArticleCancer medicine2025
Mono-TKI and TKI Plus ICI in Unresectable Hepatocellular Carcinoma Progression on First-Line Treatment of Lenvatinib: A Real-World Study.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Chinese expert consensus on the use of standardized second-line drugs for primary hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLenvatinib (LEN) is the recommended first-line therapy for unresectable hepatocellular carcinoma (uHCC), but resistance frequently develops, and limited data exist on second-line treatments. This study evaluated the efficacy and safety with a focus on the sorafenib (SOR) or regorafenib (REG)- based monotherapy or combination therapy in patients with uHCC after failure of first-line LEN.
methodsPatients with first-line LEN failure between May 2018 and December 2023 were retrospectively collected. Based on second-line regimens, 70 patients were divided into two groups: the TKI group (n = 21) and the TKI-ICI group (n = 49). Overall survival (OS) and progression-free survival (PFS) were analyzed by Kaplan-Meier methods, and multivariate analysis was performed to identify prognostic factors.
resultsIn the TKI-ICI group, median PFS was 5.27 months and median OS was 12.53 months. In the TKI group, median PFS was 3.10 months and median OS was 7.50 months. The objective response rate (ORR) was 19.1% in the TKI group and 16.3% in the TKI-ICI group. The disease control rate (DCR) was 85.7% in the TKI-ICI group and 61.9% in the TKI group. In the TKI-ICI cohort, multivariable Cox analysis revealed the high albumin to neutrophil ratio index (ANRI) was an independent predictor for PFS, while alpha-fetoprotein > 400 ng/mL was the independent predictor for OS. Safety profiles in both cohorts showed manageable toxicity, with no treatment-related deaths.
conclusionsThe combination of TKI and ICI presents a promising second-line treatment option after LEN failure, regardless of the specific second-line TKI used.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.